(19)
(11) EP 4 577 562 A1

(12)

(43) Date of publication:
02.07.2025 Bulletin 2025/27

(21) Application number: 23761879.8

(22) Date of filing: 25.08.2023
(51) International Patent Classification (IPC): 
C07K 14/47(2006.01)
A61K 39/00(2006.01)
C07K 14/725(2006.01)
C07K 14/74(2006.01)
A61P 37/02(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/4748; C07K 14/70539; A61P 37/02; C07K 14/7051; A61K 40/11; A61K 40/4268
(86) International application number:
PCT/EP2023/073331
(87) International publication number:
WO 2024/042202 (29.02.2024 Gazette 2024/09)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 26.08.2022 EP 22192464

(71) Applicant: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
13125 Berlin (DE)

(72) Inventors:
  • LORENZ, Felix
    13129 Berlin (DE)
  • CLAUSS, Julian
    13086 Berlin (DE)
  • EDES, Inan
    13156 Berlin (DE)
  • STAHN, Rainer
    13125 Berlin (DE)
  • SADA JAPP, Alberto
    10439 Berlin (DE)
  • HILGENBERG, Ellen
    10439 Berlin (DE)
  • UCKERT, Wolfgang
    13125 Berlin (DE)

(74) Representative: Moré, Solveig Helga 
Kroher Strobel Rechts- und Patentanwälte PartmbB Bavariaring 20
80336 München
80336 München (DE)

   


(54) IMMUNOTHERAPEUTICS BASED ON MAGEA1-DERIVED EPITOPES